The findings showed that the administration of UDCA led to a reduction in intracellular ROS levels within the pancreatic cancer cells. Moreover, UDCA was observed to decrease both the phosphorylation ...

Through the program, the Company will collaborate closely with forward-thinking customers to drive innovation and inform the development of future applications and assays on the platform.

CAMBRIDGE, England--(BUSINESS WIRE)--Sphere Fluidics ... innovation and inform the development of future applications and assays on the platform. Offering enhanced capabilities, including ...

School of Basic Medical Science, Xi’an Key Laboratory of Pathogenic Microorganism and Tumor Immunity, Xi’an Medical University, Xi’an 710021, China School of Biotechnology and Health Sciences, Wuyi ...

Sphere Fluidics, a leading provider of innovative ... innovation and inform the development of future applications and assays on the platform. Offering enhanced capabilities, including ...

Researchers invited to gain early access to next-generation platform to optimize functional single-cell analysis workflows across expanded applications in life science R&D CAMBRIDGE, ...

Researchers invited to gain early access to next-generation platform to optimize functional single-cell analysis workflows across expanded applications in life science R&D Cyto-Mine Chroma represents ...

The blood-based assay uses epigenomic analysis to detect circulating tumor DNA to predict cancer recurrence. "Utilizing ctDNA testing in the surveillance setting alongside standard-of-care monitoring, ...

The ChemoFx® treatment selection marker and tumor profiling assay will initially focus on ovarian and other gynecological cancers and may include testing of other major tumor types of interest ...

“There is still so much we need to learn about prostate cancer, and we eagerly look forward to seeing how this work progresses over the coming years.” Reference: Francis JC, Capper A, Rust AG, et al.